Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Charles River Laboratories International, Inc. (NYSE: CRL) provides direct access to the company’s regulatory disclosures, along with AI-powered tools that help interpret complex documents. Charles River operates in research and development in biotechnology within the professional, scientific, and technical services sector, and its filings offer detailed insight into how it manages growth, risk, governance, and capital allocation.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand segment performance across Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. These reports typically discuss demand trends, restructuring initiatives, portfolio refinement, and the use of non-GAAP measures that exclude items such as acquisition-related amortization, restructuring costs, and certain legal expenses. AI summaries can highlight key sections, such as discussions of organic revenue, operating margins, and the rationale for using non-GAAP metrics.
Current reports on Form 8-K are especially important for tracking material events at Charles River. Recent 8-K filings have described planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS, updates on Discovery and Safety Assessment demand indicators, the outcome of an SEC Division of Enforcement investigation into non-human primate sourcing, strategic review outcomes, and leadership changes including CEO succession and executive compensation arrangements. AI analysis can surface these items, explain their context, and point to related risk factor or management discussion sections in periodic reports.
Users interested in governance and executive arrangements can examine 8-K and 8-K/A filings detailing appointments, resignations, and compensation terms for senior leaders, as well as board decisions on stock repurchase authorizations and change-in-control agreements. While insider trading activity is disclosed separately on Forms 3, 4, and 5, this page is designed to link related ownership and compensation information to the broader narrative in 10-Ks, 10-Qs, and 8-Ks.
All filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help readers quickly identify the main points of lengthy documents, such as how acquisitions like K.F. (Cambodia) Ltd. and PathoQuest SAS are expected to affect Discovery and Safety Assessment or Biologics Testing operations, or how restructuring and portfolio divestitures relate to the company’s focus on core scientific capabilities and long-term shareholder value.
Form 144 filing for Charles River Laboratories International, Inc. (CRL) discloses a planned sale of 4,000 common shares through Merrill Lynch, valued at $550,000. The filer expects the transaction to occur on or about 06/23/2025. Total shares outstanding are reported at 49,115,712, so the proposed sale represents roughly 0.008% of the public float. The shares being sold were acquired on 06/02/2025 via an open-market purchase and will be settled for cash. No prior sales were reported in the past three months, and the form contains no remarks indicating special circumstances. The identity of the filer, their relationship to CRL, and any 10b5-1 plan details were not provided.
The filing is a routine notice of intent required under Rule 144 and does not, by itself, finalize the sale. Given the relatively small size versus market capitalization and the absence of additional context, the disclosure is likely to have limited market impact.